title: Recurrent peripheral facial paresis may constitute the sole clinical manifestation in neuro-behcet disease.
authors.forename: Apostolos
authors.initials: A
authors.lastname: Hatzitolios
authors.forename: Christos
authors.initials: C
authors.lastname: Savopoulos
authors.forename: George
authors.initials: G
authors.lastname: Ntaios
authors.forename: Efrosini
authors.initials: E
authors.lastname: Tsirogianni
authors.forename: Maria
authors.initials: M
authors.lastname: Baltatzi
authors.forename: Martha
authors.initials: M
authors.lastname: Apostolopoulou
authors.forename: Evaggelia
authors.initials: E
authors.lastname: Dimitrakoudi
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications* / Q000503:physiopathology*; D020516:Brachial Plexus Neuropathies / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D020427:Peroneal Neuropathies / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone